



Novo Nordisk in Massachusetts

The US Research & Development Hub, located in Greater Boston, offers extensive end-to-end capabilities across the full value chain of research and development. The coexistence of discovery, research, and innovative technology within the shared US R&D Hub positions Novo Nordisk at the forefront of groundbreaking advancements in chronic disease research in diabetes, obesity, cardiovascular, and rare blood diseases. The fully integrated US R&D Hub is comprised of scientists representative of the drug discovery and development spectrum, including the following functions: Global Drug Discovery, Global Research Technologies, Global Nucleic Acid Therapies, Digital Science & Innovation, Development's US East Coast Hub, Bio Innovation Hub and Research & Early Development Strategy, Portfolio & Operations. Collectively, the Hub offers enhanced scientific capabilities and fosters collaborative opportunities, with the goal of fueling Novo Nordisk's future discovery and development pipeline.

Vision for the future

The US R&D Hub's vision is to pioneer breakthrough sciences with seamless collaboration as an Novo Nordisk global organization.

Providing a fully integrated Hub in Greater Boston is designed to enable: the expansion of the pipeline with new modalities and mechanisms of action; accelerating drug development because of the multidisciplinary, cross-functional capabilities that include innovative technologies, discovery, research and development; access to diverse talent and thought leaders and the ability to act fast to enter new technology areas and collaborations.

Partnerships and Collaborations

Bio Innovation Hub: The Bio Innovation Hub is a cross-disciplinary R&D group based in Boston's vibrant life science ecosystem. The team co-creates novel therapeutics and delivery solutions through joint exploration of emerging science and new platforms. The Bio Innovation Hub is an integral part of the Novo Nordisk innovation ecosystem, working with external biotech, academia and research hospitals, venture and accelerator partners to co-create therapeutic solutions within cardiometabolic and rare diseases. Partnerships include Flagship Pioneering, LAB eN² and Metaphore Biotechnologies.

Clinical research partnerships

Novo Nordisk strategically pursues innovative partnerships and collaborations within the Boston biotech/pharma ecosystem with the goal of pursuing scientific innovation and technologies.

Within Development's US East Coast Hub, the team partners with organizations to bring together the best science and technology to pursue revolutionary breakthroughs. Current collaborations include MIT, Harvard University, Boston University, Massachusetts General Hospital and Beth Israel Lahey Health.

For the community

The US R&D Hub is focused on giving back to the communities in which we live and work. Leaders and scientists participate in external opportunities that highlight Novo Nordisk's commitment to the community and our internal talent with organizations such as MassBio and Women in Bio.

Location established 2021



450 EMPLOYEES



SITE MILESTONES

2023: Completed construction of state-of-the-art laboratory for Global Nucleic Acid Therapies unit, which focuses on discovery science in protein/peptide engineering and RNAi.

2023: Secured additional location in Waltham, MA for the US R&D Hub, which includes 185,000 sq feet of additional state-of-the-art laboratory and office space. Completion expected in 2026.



SITE AWARDS

Built In 2024 Best Places to Work award



Below:
One of the US R&D Hub
buildings: 75 Hayden



75 Hayden Ave,
Lexington, MA 02421

About Novo Nordisk in the U.S.:

Novo Nordisk is a leading global healthcare company that has been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity and rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With U.S. headquarters in New Jersey and commercial, production and research facilities in seven states plus Washington DC, Novo Nordisk employs approximately 8,000 people throughout the country. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.